Johnson & Johnson on Tuesday stated it is able to now not offer a forecast for sales of its COVID-19 vaccine, as vaccine hesitancy in low-income countries paired with already low demand in better-profit countries has caused a glut of supply.

The company had earlier predicted as a lot as $3.5 billion in 2022 income from the unmarried-dose vaccine, as soon as touted as an important device for vaccinating difficult-to-reach regions.

J&J also cut each end of its full-year income forecast by 25 cents and now expects to earn $10.15 to $10.35 consistent with share. But it blamed the circulating on foreign money fluctuations instead of essential business issues and raised its dividend by 6.6%, and shares rise about 4%.

MODERNA SAYS DUAL VARIANT BOOSTER PROVIDES BETTER PROTECTION

“With the guidance cut driven exclusively by currency, I think shares are reacting to the forward-looking comments,” said Edward Jones analyst Ashtyn Evans. “J&J mentioned accelerating boom in clinical era thru acquisitions and also the belief that supply chain problems will improve within the 2nd 1/2 of the year.”

Other analysts stated that J&J stays a secure guess in the healthcare region and that elevating the dividend furnished predictable profits for investors in spite of vaccine income woes.

The J&J shot has been hurt via links to uncommon but doubtlessly lethal blood clots, manufacturing troubles, and worries approximately efficacy. It accounts for approximately 3% of all doses administered within the United States, and roughly 2% of doses in Europe.

Company executives said lack of popularity in lower-earnings international locations also turned into hurting vaccine sales. According to the World Health Organization, poorer international locations have requested inadequate doses to meet its purpose of vaccinating at least 70% of their populations with the aid of the middle of the year.

The vaccine, that’s offered at a now not-for-earnings charge, brought in $457 million in the first area. J&J recorded a vaccine income of $2.39 billion last year.

Pfizer Inc has predicted $32 billion in 2022 sales from its COVID vaccine advanced with BioNTech SE], at the same time as Moderna Inc has forecast $21 billion for its shot this year.